Table 8. Treatment outcomes for patients with and without acquired drug resistance to anti-TB drugs, England, Wales, and Northern Ireland, 2001–2013*.
| Outcomes |
Acquired drug resistance category |
||||
| No MDR TB before or after acquiring resistance, no. (%) |
Acquired resistance that resulted in MDR TB, no. (%) |
Initial MDR TB with additional acquired resistance, no. (%) |
Total with acquired drug resistance, no. (%) |
No acquired drug resistance, no. (%) |
|
| Treatment completed | 39 (65) | 20 (48.8) | 27 (69.2) | 86 (61.4) | 45,690 (79.9 |
| Died | 1 (1.7) | 8 (19.5) | 1 (2.6) | 10 (7.1) | 2,651 (4.6) |
| Lost to follow-up | 5 (8.3) | 5 (12.2) | 3 (7.7) | 13 (9.3) | 3,046 (5.3) |
| Still receiving treatment | 10 (16.7) | 7 (17.1) | 5 (12.8) | 22 1(5.7) | 1,253 (2.2) |
| Treatment stopped | 2 (3.3) | 1 (2.4) | 3 (7.7) | 6 (4.3) | 410 (0.7) |
| Not evaluated | 3 (5) | 0 | 0 | 3 (2.1) | 4,159 (7.3) |
*MDR, multidrug resistant; TB, tuberculosis.